US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hersha Hospitality

9.99

+0.0000

Volume:- -

Turnover:- -

Market Cap:402.56M

PE:51.37

High:9.99

Open:9.99

Low:9.99

Close:9.99

Loading ...

Overview Company News Filings

Natera (NasdaqGS:NTRA) Unveils DEFINE-HT Trial Insights in Heart Transplantation Study

Simply Wall St.

HT Labs triumphs at WAN-IFRA South Asian Digital Media Awards 2025

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Hoth Therapeutics reports data from its Alzheimer’s candidate HT-ALZ

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

Hoth Therapeutics announces ‘positive’ results from study of HT-KIT

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Hoth Therapeutics Reports HT-001 Cream Efficacy in Case Study

MT Newswires Live

Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

HT Media's Consolidated Net Loss Shrinks in Fiscal Q3

MT Newswires Live

HT Media Gets Board Nod to Invest Additional INR110 Million in Wholly-Owned Arm; Shares Up 4%

MT Newswires Live

HT Media Names CEO

MT Newswires Live

Hoth Therapeutics: Enrollment in HT-001 trial proceeding as planned

D. Boral says Hoth findings highlight HT-001 potential to ‘revolutionize’ care

Hoth Therapeutics reports ‘encouraging’ results from Phase 2a trial of HT-001

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/HT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HT\",,,,,undefined,":{"symbol":"HT","market":"US","secType":"STK","nameCN":"Hersha Hospitality","latestPrice":9.99,"timestamp":1746561600000,"preClose":9.99,"halted":0,"volume":0,"delay":0,"floatShares":28161358,"shares":40296166,"eps":0.194475,"marketStatus":"Closed","change":0,"latestTime":"05-06 16:00:00 EDT","open":9.99,"high":9.99,"low":9.99,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.194475,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746604800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":916894800000,"exchange":"NYSE","adjPreClose":9.99,"dividendRate":0.02002,"volumeRatio":0,"impliedVol":1.5696,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HT\",,,,,undefined,":{"symbol":"HT","floatShares":28161358,"roa":"1.16%","roe":"4.60%","lyrEps":3.082098,"shares":40296166,"dividePrice":0.2,"high":9.99,"amplitude":0,"preClose":9.99,"low":9.99,"week52Low":9.99,"pbRate":"0.61","psRate":"1.11","week52High":9.99,"institutionHeld":0.686,"latestPrice":9.99,"eps":0.194475,"divideRate":0.02002,"volume":0,"delay":0,"ttmEps":0.194475,"open":9.99,"prevYearClose":9.99,"prevWeekClose":9.99,"prevMonthClose":9.99,"prevQuarterClose":9.99,"fiveDayClose":9.99,"twentyDayClose":9.99,"sixtyDayClose":9.99},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532648670","title":"Natera (NasdaqGS:NTRA) Unveils DEFINE-HT Trial Insights in Heart Transplantation Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2532648670","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532648670?lang=en_us&edition=fundamental","pubTime":"2025-05-01 01:59","pubTimestamp":1746035964,"startTime":"0","endTime":"0","summary":"Natera saw a 7.61% increase in its share price over the last month, potentially buoyed by the release of promising DEFINE-HT clinical trial results. These results highlighted the strong predictive ability of their Prospera test in heart transplant patient monitoring, providing significant insights into patient outcomes. Additionally, the launch of the Signatera Genome assay might have bolstered investor confidence in Natera's innovative capabilities across cancer diagnostics. Amidst a broad market trend of a 5.2% rise over the same period, Natera's advancements in genomic testing added positive weight to its stock performance.We've identified 1 risk for Natera that you should be aware of.Despite trading below the consensus analyst price target of US$187.72, the current share price offers a significant discount. This movement could reflect market optimism regarding the company's long-term growth prospects, although considerations around profitability remain due to current unprofitabilit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-nasdaqgs-ntra-unveils-define-175924242.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0963586101.USD","BK4139","BK4218","LU0053671581.USD","LU2065170008.USD","LU0012050646.USD","LU2065171402.SGD","LU1064131342.USD","LU2324357040.USD","LU2065169927.USD","LU2065171311.SGD","NTRA","LU2264538146.SGD","LU2065731478.USD","BK4181","LU0106261612.USD","LU1988902786.USD","HT"],"gpt_icon":0},{"id":"2529358757","title":"HT Labs triumphs at WAN-IFRA South Asian Digital Media Awards 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529358757","media":"ByHT News Desk","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529358757?lang=en_us&edition=fundamental","pubTime":"2025-04-22 02:18","pubTimestamp":1745259480,"startTime":"0","endTime":"0","summary":"The WAN-IFRA South Asian Digital Media Awards are among the most respected honours in the industry, judged by a panel of distinguished international experts. They spotlight organisations that demonstr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.hindustantimes.com/business/ht-labs-triumphs-at-wan-ifra-south-asian-digital-media-awards-2025-secures-5-wins-for-ottplay-and-slurrp-101745259307757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"hindustan_highlight","symbols":["BK4218","BK4181","IFRA","BK4585","BK4588","HT"],"gpt_icon":0},{"id":"2524460118","title":"Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ","url":"https://stock-news.laohu8.com/highlight/detail?id=2524460118","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524460118?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:02","pubTimestamp":1743595320,"startTime":"0","endTime":"0","summary":"NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. , a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to advance Alzheimer's disease research through a novel therapeutic strategy. The partnership centers on a recently submitted NIH grant proposal focused on studying HT-ALZ—an FDA-approved NK-1 receptor antagonist—for its potential to reduce neuroinflammation and improve cognitive function in Alzheimer's disease .The research collaboration is led by Dr. Carla M. Yuede, Professor in the Departments of Psychiatry, Neurology, and Neuroscience, and Director of the Animal Behavior Core at Washington University. The proposal, titled \"Cell Type Specificity of Neurokinin-1 Receptor Antagonists on Cognitive Improvement,\" aims to understand the precise neurological mechanisms and cellular targets responsible for the beneficial cognitive effects observed with HT-ALZ.Robb Knie, Chief","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hoth-therapeutics-collaborates-washington-university-120200822.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hoth-therapeutics-collaborates-washington-university-120200822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","WASH","HOTH","BK4007","HT","BK4211","BK4181"],"gpt_icon":0},{"id":"2524467185","title":"Hoth Therapeutics reports data from its Alzheimer’s candidate HT-ALZ","url":"https://stock-news.laohu8.com/highlight/detail?id=2524467185","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524467185?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:00","pubTimestamp":1743595228,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics (HOTH) announced groundbreaking preclinical data supporting the therapeutic potential of its lead Alzheimer’s candidate, HT-ALZ, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hoth-therapeutics-reports-data-from-its-alzheimers-candidate-ht-alz?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hoth-therapeutics-reports-data-from-its-alzheimers-candidate-ht-alz?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HOTH","BK4181","BK4218","HT","BK4007"],"gpt_icon":0},{"id":"2524970178","title":"Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=2524970178","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524970178?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:45","pubTimestamp":1743453900,"startTime":"0","endTime":"0","summary":"NEW YORK, March 31, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. ,a patient-focused clinical-stage biopharmaceutical company, today announced that it has received an official Filing Receipt from the United States Patent and Trademark Office  for a new patent application related to the proprietary formulation of HT-001, the Company's lead clinical asset.This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hoth-therapeutics-receives-uspto-filing-204500312.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hoth-therapeutics-receives-uspto-filing-204500312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4181","BK4218","HOTH","HT"],"gpt_icon":0},{"id":"2522805904","title":"Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation","url":"https://stock-news.laohu8.com/highlight/detail?id=2522805904","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522805904?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:02","pubTimestamp":1742990520,"startTime":"0","endTime":"0","summary":"NEW YORK, March 26, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc., a biopharmaceutical company focused on developing first-in-class therapies for allergic and inflammatory diseases, today announced two major developments in the ongoing advancement of its proprietary antisense oligonucleotide  cancer fighting drug candidate,HT-KIT.The Company has filedamended claimswith the U.S. Patent and Trademark Office for its lead ASO technology targetingMS4A6A and FcεRIβ—genes implicated in allergic inflammation and mast cell-related diseases. These refined claims enhance intellectual property protection for HT-KIT and further position it as a novel therapeutic platform with broad clinical potential, including use in treating conditions such as anaphylaxis, mastocytosis, and allergic asthma.In parallel, Hoth has initiated aGLP-compliant 4-week intravenous toxicity studywith a 14-day recovery period in C57BL/6 mice. This preclinical study, conducted in partnership with OnTargetx R&D Inc. and ITR Lab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hoth-therapeutics-advances-cancer-fighting-120200158.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hoth-therapeutics-advances-cancer-fighting-120200158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4561","BK4007","BK4218","HOTH","BK4200","ASO","BK4181","HT"],"gpt_icon":0},{"id":"2522026527","title":"DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2522026527","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522026527?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:00","pubTimestamp":1742900400,"startTime":"0","endTime":"0","summary":"First-of-its-kind prospective trial evaluates the association between dd-cfDNA and clinical outcomes in heart transplantation using Prospera Heart with Donor Quantity Score . AUSTIN, Texas, March 25, 2025----Natera, Inc. , a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation  45th Annual Meeting on April 29, 2025.The Prospera test leverages Natera’s core single-nucleotide -based massively multiplexed PCR  technology to identify allograft rejection non-invasively and with high precision and accuracy, without the need for prior donor or recipient genotyping. The test works by measuring the fraction of donor-derived cell-free DNA  in the recipient’s blood. It may be used by physicians considering the diagnosis of active rejection, helping to rule in or out this condition when evaluating the need for diagnostic testing or the re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/define-ht-selected-breaking-oral-110000797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU1064131342.USD","CLIA","LU2065170008.USD","LU2065169927.USD","LU0963586101.USD","LU2065731478.USD","LU1988902786.USD","BK4139","BK4218","LU0012050646.USD","HT","LU2065171311.SGD","LU2264538146.SGD","LU0053671581.USD","LU0106261612.USD","BK4588","EMB","LU2324357040.USD","BK4181","LU2065171402.SGD","NTRA"],"gpt_icon":0},{"id":"2520821951","title":"Hoth Therapeutics announces ‘positive’ results from study of HT-KIT","url":"https://stock-news.laohu8.com/highlight/detail?id=2520821951","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520821951?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:11","pubTimestamp":1742386281,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics  announced breakthrough preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors. The results highlight HT-KIT’s ability to significantly reduce tumor burden in humanized mouse models, disrupt KIT signaling pathways, and induce tumor cell death. Key Findings from the preclinical study: Significant Reduction in KIT Expression – HT-KIT effectively reduced KIT receptor expression within 24 hours, with effects sustained for 72 hours. Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment, while the lower dose led to delayed but substantial cell death at 72 hours. Decreased Tumor Cell Proliferation – HT-KIT treatment inhibited cell growth and proliferation in GIST-T1 cells, as confirmed by cell count reductions and decreased fluorescence intensity in proliferation assays. Marked Tumor Volume Reduction in GIST Mouse Models – In a humanized xenograft mode","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hoth-therapeutics-announces-positive-results-121121383.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hoth-therapeutics-announces-positive-results-121121383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","HT","BK4218","BK4007","HOTH"],"gpt_icon":0},{"id":"2520678219","title":"Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2520678219","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520678219?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:06","pubTimestamp":1742299560,"startTime":"0","endTime":"0","summary":"New Data Demonstrates Significant Reduction in Tumor Growth and KITExpression in Preclinical GIST Models. Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment, while the lower dose led to delayed but substantial cell death at 72 hours.Decreased Tumor Cell Proliferation – HT-KIT treatment inhibited cell growth and proliferation in GIST-T1 cells, as confirmed by cell count reductions and decreased fluorescence intensity in proliferation assays.Marked Tumor Volume Reduction in GIST Mouse Models – In a humanized xenograft model, HT-KIT treatment  led to a significant reduction in tumor growth, with differences becoming statistically significant by day 8 and increasing over time.Consistent Tumor Size Reduction – Excised tumors from HT-KIT-treated mice were smaller and lighter than those in the control group, reinforcing tumor volume measurements.NEW YORK, March 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. , a clinical-stage bi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hoth-therapeutics-announces-positive-preclinical-120600551.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hoth-therapeutics-announces-positive-preclinical-120600551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","HOTH","BK4218","BK4212","POST","BK4181","HT"],"gpt_icon":0},{"id":"2518226325","title":"Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need","url":"https://stock-news.laohu8.com/highlight/detail?id=2518226325","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518226325?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:02","pubTimestamp":1741608120,"startTime":"0","endTime":"0","summary":"NEW YORK, March 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to developing innovative therapies, today announced its intention to submit an Expanded Access application for HT-001, its novel therapeutic candidate for the treatment of dermatological conditions associated with cancer therapy.HT-001 is being developed to alleviate the adverse dermatological effects experienced by cancer patients undergoing epidermal growth factor receptor  inhibitor treatments. With positive progress in ongoing clinical studies, Hoth Therapeutics aims to provide patients access to HT-001 outside of traditional clinical trials through the Expanded Access Program , commonly known as \"compassionate use.\". \"Submitting an Expanded Access application is an important step in our commitment to ensuring patients who may benefit from HT-001 have the opportunity to receive this promising treatment,\" said Robb Knie, CEO of Hoth Therapeutics. \"We remain dedicat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hoth-therapeutics-announces-plans-submit-120200268.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hoth-therapeutics-announces-plans-submit-120200268.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4181","HOTH","HT","BK4218"],"gpt_icon":0},{"id":"2517417923","title":"Hoth Therapeutics Reports HT-001 Cream Efficacy in Case Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2517417923","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517417923?lang=en_us&edition=fundamental","pubTime":"2025-03-06 03:21","pubTimestamp":1741202501,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics  said Wednesday its therapeutic candidate, HT-001, showed \"promising\" results in a patient with metastatic breast cancer undergoing treatment with paclitaxel, trastuzumab, and pertuzumab.The patient developed pruritic, burning red papules on the face, scalp, and upper back, a known dermatologic side effect of EGFR inhibitors, the company said.\"After just one week of applying HT-001 2% cream twice daily, the patient experienced full symptom and lesion resolution, with no recurrence of lesions in the following three weeks,\" it said.The data will be presented at the upcoming American Academy of Dermatology annual meeting, Hoth said. A phase 2A trial of HT-001 in a broader patient population is being conducted.The shares were over 7% lower in recent trading.Price: 1.15, Change: -0.10, Percent Change: -7.66","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01611","BK4007","HT","BK4218","HOTH","BK1167","BK4181","BK1612"],"gpt_icon":0},{"id":"2517238769","title":"Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2517238769","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517238769?lang=en_us&edition=fundamental","pubTime":"2025-03-06 02:46","pubTimestamp":1741200367,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics (HOTH) announced “promising” findings for its novel therapeutic candidate, HT-001, a topical neurokinin 1 receptor antagonist, in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hoth-therapeutics-reports-promising-results-for-ht-001-therapeutic-candidate?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hoth-therapeutics-reports-promising-results-for-ht-001-therapeutic-candidate?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4218","BK4007","HT","BK4181","HOTH"],"gpt_icon":0},{"id":"2517923392","title":"Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517923392","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517923392?lang=en_us&edition=fundamental","pubTime":"2025-03-06 02:40","pubTimestamp":1741200000,"startTime":"0","endTime":"0","summary":"The recent case study will be highlighted that demonstrated the efficacy of HT-001 2% cream in a 59-year-old patient with metastatic breast cancer undergoing treatment with paclitaxel, trastuzumab, and pertuzumab. The patient developed pruritic, burning red papules on the face, scalp, and upper back, a known dermatologic side effect of EGFR inhibitors. After just one week of applying HT-001 2% cream twice daily, the patient experienced full symptom and lesion resolution, with no recurrence of lesions in the following three weeks.NEW YORK, March 5, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. , a patient-focused biopharmaceutical company, is excited to announce promising findings for its novel therapeutic candidate, HT-001, a topical neurokinin 1 receptor  antagonist, in the treatment of Epidermal Growth Factor Receptor Inhibitor-Associated Papulopustular Eruptions .The data will be presented at the American Academy of Dermatology  2025 Annual Meeting, which takes place March 7-11, 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hoth-therapeutics-announces-positive-results-184000046.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hoth-therapeutics-announces-positive-results-184000046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","AFG","BK4218","HT","HOTH","BK4007","BK4107","BK4117"],"gpt_icon":0},{"id":"2510857681","title":"Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic","url":"https://stock-news.laohu8.com/highlight/detail?id=2510857681","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510857681?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:22","pubTimestamp":1739193720,"startTime":"0","endTime":"0","summary":"Development and optimization of staining methods for  markers, a critical target in HT-KIT therapeutic mechanism.Processing and qualitative evaluation of tissue samples by a board-certified pathologist to determine the presence of markers.Comprehensive reporting and insights to support the continued development of HT-KIT.\"This partnership is instrumental in our efforts to advance HT-KIT, a promising therapeutic aimed at targeting c-Kit in cancer treatments,\" said Robb Knie, CEO at Hoth Therapeutics. \"We are committed to driving innovative solutions that can transform patient care.\". The study aligns with Hoth Therapeutics' mission to accelerate groundbreaking therapies and address unmet medical needs in oncology.HT-KIT is Hoth's preclinical therapeutic candidate targeting c-Kit, a receptor tyrosine kinase involved in various cancers. This candidate represents a potential advancement in precision oncology therapies.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hoth-therapeutics-partners-ontargetx-r-132200293.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hoth-therapeutics-partners-ontargetx-r-132200293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","BK4007","BK4181","HT","HOTH"],"gpt_icon":0},{"id":"2508455470","title":"HT Media's Consolidated Net Loss Shrinks in Fiscal Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2508455470","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508455470?lang=en_us&edition=fundamental","pubTime":"2025-02-04 20:51","pubTimestamp":1738673463,"startTime":"0","endTime":"0","summary":"HT Media  consolidated net loss attributable to owners stood at 59.9 million Indian rupees in the fiscal third quarter, shrinking from a loss of 131.2 million rupees a year ago, according to an Indian bourse filing on Tuesday by the mass media company.Loss per share during the quarter ended Dec. 31, 2024, came in at 0.26 rupees, versus loss per share of 0.57 rupees a year earlier.Revenue from operations rose year on year to 4.90 billion rupees from 4.43 billion rupees, according to the filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CNSL","BK4115","BK4218","01611","BK4181","HT"],"gpt_icon":0},{"id":"2508355124","title":"HT Media Gets Board Nod to Invest Additional INR110 Million in Wholly-Owned Arm; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508355124","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508355124?lang=en_us&edition=fundamental","pubTime":"2025-02-04 17:21","pubTimestamp":1738660869,"startTime":"0","endTime":"0","summary":"HT Media  has received board nod to invest up to 110 million Indian rupees in its wholly-owned subsidiary Mosaic Media Ventures, according to a Tuesday filing with the Indian bourses.The company will acquire 54,428 equity shares at the price of 10 rupees per equity share at the face value of 10 rupees per equity share and a premium of 2,011 rupees per equity share.The investment will be used by the subsidiary to further grow its business of gathering and distributing news, analysis and research for business, management, investors, and general public.Shares of the company were up 4% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HT","IE00BMPRXN33.USD","BK4585","01611","IE00BMPRXR70.SGD","LU0348723411.USD","BK4218","IE00BMPRXQ63.HKD","BK4141","BK4543","BK4588","BK4181"],"gpt_icon":1},{"id":"2503315847","title":"HT Media Names CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2503315847","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503315847?lang=en_us&edition=fundamental","pubTime":"2025-01-13 08:14","pubTimestamp":1736727250,"startTime":"0","endTime":"0","summary":"Indian media house HT Media  has appointed Sameer Singh as group chief executive officer and key managerial personnel, with effect from March 1, according to a Saturday filing to the stock exchanges.Singh will take over from Praveen Someshwar, who has resigned from the position of managing director and CEO with effect from Feb. 28.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HT","BK1167","BK4218","BK4181","BK1612","01611"],"gpt_icon":0},{"id":"2502709497","title":"Hoth Therapeutics: Enrollment in HT-001 trial proceeding as planned","url":"https://stock-news.laohu8.com/highlight/detail?id=2502709497","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502709497?lang=en_us&edition=fundamental","pubTime":"2025-01-09 02:30","pubTimestamp":1736361027,"startTime":"0","endTime":"0","summary":"13:29 EST Hoth Therapeutics (HOTH): Enrollment in HT-001 trial proceeding as planned Published first on TheFly – the ultimate source for real-time,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hoth-therapeutics-enrollment-in-ht-001-trial-proceeding-as-planned?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hoth-therapeutics-enrollment-in-ht-001-trial-proceeding-as-planned?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4218","HT","BK4181","BK4007","HOTH"],"gpt_icon":0},{"id":"2501782952","title":"D. Boral says Hoth findings highlight HT-001 potential to ‘revolutionize’ care","url":"https://stock-news.laohu8.com/highlight/detail?id=2501782952","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501782952?lang=en_us&edition=fundamental","pubTime":"2025-01-08 00:35","pubTimestamp":1736267731,"startTime":"0","endTime":"0","summary":"After Hoth Therapeutics (HOTH) announced interim results from its Phase 2a CLEER-001 trial evaluating HT-001, a treatment for skin toxicities cause...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/d-boral-says-hoth-findings-highlight-ht-001-potential-to-revolutionize-care?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/d-boral-says-hoth-findings-highlight-ht-001-potential-to-revolutionize-care?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4181","HOTH","BK4218","HT"],"gpt_icon":0},{"id":"2501201520","title":"Hoth Therapeutics reports ‘encouraging’ results from Phase 2a trial of HT-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2501201520","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501201520?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:36","pubTimestamp":1736256976,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics (HOTH) shared encouraging interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address ski...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hoth-therapeutics-reports-encouraging-results-from-phase-2a-trial-of-ht-001?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hoth-therapeutics-reports-encouraging-results-from-phase-2a-trial-of-ht-001?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HOTH","BK4218","BK4007","HT","BK4181"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":22,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2023-11-28","symbol":"HT","reason":null,"defaultRemindTime":1701181800000,"announcedDate":"2023-11-22","type":"delisting","dateTimestamp":1701147600000},{"market":"US","date":"2023-11-09","symbol":"HT","fiscalQuarterEnding":"2023/09","expectedEps":0.22,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1699506000000,"reportTimeType":"post","actualEps":0.2},{"date":"2023-09-28","symbol":"HT","amount":0.05,"announcedDate":"2023-09-13","type":"dividend","market":"US","newRecordDate":"2023-09-29","defaultRemindTime":1695907800000,"name":"HT基金","recordDate":"2023-10-16","payableDate":"2023-09-29","currency":"USD","dateTimestamp":1695873600000,"payDate":"2023-10-16"},{"date":"2023-08-02","symbol":"HT","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2023/06","expectedEps":0.36,"defaultRemindTime":1691006400000,"name":null,"time":"Post Market","dateTimestamp":1690948800000,"actualEps":null},{"date":"2023-06-29","symbol":"HT","amount":0.05,"announcedDate":"2023-05-18","type":"dividend","market":"US","newRecordDate":"2023-06-30","defaultRemindTime":1688045400000,"name":"HT基金","recordDate":"2023-07-17","payableDate":"2023-06-30","currency":"USD","dateTimestamp":1688011200000,"payDate":"2023-07-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HT\",market:\"US\",,,undefined,":[{"executeDate":"2017-03-29","recordDate":"2017-03-31","paymentDate":"2017-04-17","value":0.28,"currency":"USD"},{"executeDate":"2017-06-28","recordDate":"2017-06-30","paymentDate":"2017-07-17","value":0.28,"currency":"USD"},{"executeDate":"2017-09-28","recordDate":"2017-09-29","paymentDate":"2017-10-13","value":0.28,"currency":"USD"},{"executeDate":"2018-01-04","recordDate":"2018-01-05","paymentDate":"2018-01-16","value":0.28,"currency":"USD"},{"executeDate":"2018-03-28","recordDate":"2018-03-29","paymentDate":"2018-04-13","value":0.28,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":9,"updateTime":1693717200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HT","date":"2023-11-28","current":12.062768,"percent":0.788835,"low":-848.596254,"twenty":-10.554667,"median":-2.903703,"eighty":63.998951,"high":282.105202,"avg":-12.20736,"sd":187.759719,"marketCap":402558698},"quantilePoints":[{"date":"2020-05-08","current":-10.300391,"twenty":6.394647,"median":13.51509,"eighty":28.645476,"marketCap":203793228},{"date":"2020-05-15","current":-8.88789,"twenty":6.381044,"median":13.470104,"eighty":28.645476,"marketCap":175846899},{"date":"2020-05-22","current":-10.213467,"twenty":6.370558,"median":13.418745,"eighty":28.645476,"marketCap":202073454},{"date":"2020-05-29","current":-10.952314,"twenty":6.366908,"median":13.396397,"eighty":28.645476,"marketCap":216691534},{"date":"2020-06-05","current":-19.753281,"twenty":6.35956,"median":13.337597,"eighty":28.645476,"marketCap":390818659},{"date":"2020-06-12","current":-15.885202,"twenty":6.350848,"median":13.210512,"eighty":28.645476,"marketCap":314288713},{"date":"2020-06-19","current":-13.538277,"twenty":6.344297,"median":13.1103,"eighty":28.645476,"marketCap":267854812},{"date":"2020-06-26","current":-11.799815,"twenty":6.332599,"median":13.018608,"eighty":28.645476,"marketCap":233459331},{"date":"2020-07-02","current":-11.843276,"twenty":6.319963,"median":12.944936,"eighty":28.645476,"marketCap":234319218},{"date":"2020-07-10","current":-11.995392,"twenty":6.296324,"median":12.851583,"eighty":28.645476,"marketCap":237328823},{"date":"2020-07-17","current":-12.038853,"twenty":6.246265,"median":12.773324,"eighty":28.556232,"marketCap":238188710},{"date":"2020-07-24","current":-10.713275,"twenty":-9.005236,"median":12.70118,"eighty":28.34558,"marketCap":211962155},{"date":"2020-07-31","current":-10.343852,"twenty":-9.99616,"median":12.623103,"eighty":28.34558,"marketCap":204653115},{"date":"2020-08-07","current":-3.346882,"twenty":-10.265621,"median":12.559323,"eighty":28.34558,"marketCap":291530190},{"date":"2020-08-14","current":-3.453374,"twenty":-10.265621,"median":12.510191,"eighty":28.34558,"marketCap":300806151},{"date":"2020-08-21","current":-3.093331,"twenty":-10.265621,"median":12.464702,"eighty":28.34558,"marketCap":269444570},{"date":"2020-08-28","current":-3.453374,"twenty":-10.265621,"median":12.416803,"eighty":28.34558,"marketCap":300806151},{"date":"2020-09-04","current":-3.402664,"twenty":-10.265621,"median":12.366166,"eighty":28.34558,"marketCap":296389027},{"date":"2020-09-11","current":-3.002052,"twenty":-10.265621,"median":12.251866,"eighty":28.34558,"marketCap":261493746},{"date":"2020-09-18","current":-3.017265,"twenty":-10.265621,"median":12.197919,"eighty":28.34558,"marketCap":262818883},{"date":"2020-09-25","current":-2.728216,"twenty":-10.265621,"median":12.167548,"eighty":28.34558,"marketCap":237641276},{"date":"2020-10-02","current":-2.900631,"twenty":-10.265621,"median":12.11716,"eighty":28.34558,"marketCap":252659498},{"date":"2020-10-09","current":-2.819495,"twenty":-10.265621,"median":12.078317,"eighty":28.34558,"marketCap":245592099},{"date":"2020-10-16","current":-2.571014,"twenty":-10.265621,"median":12.036444,"eighty":28.34558,"marketCap":223948191},{"date":"2020-10-23","current":-2.687648,"twenty":-10.265621,"median":11.956978,"eighty":28.34558,"marketCap":234107577},{"date":"2020-10-30","current":-2.484807,"twenty":-10.265621,"median":11.900174,"eighty":28.34558,"marketCap":216439080},{"date":"2020-11-06","current":-2.510162,"twenty":-10.265621,"median":11.858326,"eighty":28.34558,"marketCap":218647642},{"date":"2020-11-13","current":-2.258213,"twenty":-10.265621,"median":11.786061,"eighty":28.34558,"marketCap":295498417},{"date":"2020-11-20","current":-2.444143,"twenty":-10.265621,"median":11.699907,"eighty":28.34558,"marketCap":319828376},{"date":"2020-11-27","current":-2.893758,"twenty":-10.265621,"median":11.588298,"eighty":28.34558,"marketCap":378662642},{"date":"2020-12-04","current":-3.177724,"twenty":-10.265621,"median":11.504159,"eighty":28.34558,"marketCap":415821126},{"date":"2020-12-11","current":-2.84643,"twenty":-10.265621,"median":11.41237,"eighty":28.34558,"marketCap":372469561},{"date":"2020-12-18","current":-2.778819,"twenty":-10.265621,"median":11.247311,"eighty":28.34558,"marketCap":363622303},{"date":"2020-12-24","current":-2.711207,"twenty":-10.265621,"median":10.979123,"eighty":28.34558,"marketCap":354775045},{"date":"2020-12-31","current":-2.66726,"twenty":-10.265621,"median":10.751448,"eighty":28.34558,"marketCap":349024328},{"date":"2021-01-08","current":-2.653738,"twenty":-10.265621,"median":10.673856,"eighty":28.34558,"marketCap":347254876},{"date":"2021-01-15","current":-2.704446,"twenty":-10.265621,"median":10.673856,"eighty":28.34558,"marketCap":353890320},{"date":"2021-01-22","current":-2.643596,"twenty":-10.265621,"median":10.673856,"eighty":28.34558,"marketCap":345927787},{"date":"2021-01-29","current":-2.582746,"twenty":-10.265621,"median":10.673856,"eighty":28.34558,"marketCap":337965255},{"date":"2021-02-05","current":-2.738252,"twenty":-10.265621,"median":10.673856,"eighty":28.34558,"marketCap":358313949},{"date":"2021-02-12","current":-2.886996,"twenty":-10.265621,"median":10.673856,"eighty":28.34558,"marketCap":377777916},{"date":"2021-02-19","current":-3.360275,"twenty":-10.265621,"median":10.673856,"eighty":28.34558,"marketCap":439708722},{"date":"2021-02-26","current":-2.981457,"twenty":-10.265621,"median":10.673856,"eighty":28.34558,"marketCap":491907544},{"date":"2021-03-05","current":-2.914427,"twenty":-10.283006,"median":10.644261,"eighty":28.431087,"marketCap":480848472},{"date":"2021-03-12","current":-3.246892,"twenty":-10.265621,"median":10.571693,"eighty":28.34558,"marketCap":535701471},{"date":"2021-03-19","current":-3.110153,"twenty":-10.265621,"median":10.486422,"eighty":28.34558,"marketCap":513140964},{"date":"2021-03-26","current":-3.000225,"twenty":-10.248237,"median":10.412435,"eighty":28.260073,"marketCap":495004085},{"date":"2021-04-01","current":-2.901072,"twenty":-10.248237,"median":10.249664,"eighty":28.260073,"marketCap":478644986},{"date":"2021-04-09","current":-2.822811,"twenty":-10.265621,"median":10.269394,"eighty":28.34558,"marketCap":465732702},{"date":"2021-04-16","current":-2.871387,"twenty":-10.265621,"median":10.044319,"eighty":28.34558,"marketCap":473747223},{"date":"2021-04-23","current":-2.825509,"twenty":-10.265621,"median":9.697285,"eighty":28.34558,"marketCap":466177954},{"date":"2021-04-30","current":-3.87863,"twenty":-10.248237,"median":8.232069,"eighty":28.260073,"marketCap":521070710},{"date":"2021-05-07","current":-3.902117,"twenty":-10.248237,"median":8.034644,"eighty":28.260073,"marketCap":524225983},{"date":"2021-05-14","current":-3.707514,"twenty":-10.248237,"median":7.78895,"eighty":28.260073,"marketCap":498082297},{"date":"2021-05-21","current":-3.435742,"twenty":-10.248237,"median":7.711362,"eighty":28.260073,"marketCap":461571287},{"date":"2021-05-28","current":-3.606858,"twenty":-10.248237,"median":7.672568,"eighty":28.260073,"marketCap":484559700},{"date":"2021-06-04","current":-3.821592,"twenty":-10.248237,"median":7.569118,"eighty":28.260073,"marketCap":513407906},{"date":"2021-06-11","current":-4.029615,"twenty":-10.248237,"median":7.482909,"eighty":28.260073,"marketCap":541354605},{"date":"2021-06-18","current":-3.791395,"twenty":-10.248237,"median":7.405321,"eighty":28.260073,"marketCap":509351127},{"date":"2021-06-25","current":-3.764553,"twenty":-10.248237,"median":7.29595,"eighty":28.260073,"marketCap":505745101},{"date":"2021-07-02","current":-3.626989,"twenty":-10.248237,"median":7.252941,"eighty":28.260073,"marketCap":487264220},{"date":"2021-07-09","current":-3.469294,"twenty":-10.248237,"median":7.190382,"eighty":28.260073,"marketCap":466078819},{"date":"2021-07-16","current":-3.274691,"twenty":-10.248237,"median":7.053534,"eighty":28.260073,"marketCap":439935132},{"date":"2021-07-23","current":-3.167324,"twenty":-10.248237,"median":6.987065,"eighty":28.260073,"marketCap":425511030},{"date":"2021-07-30","current":-4.453163,"twenty":-10.248237,"median":6.920596,"eighty":28.260073,"marketCap":425143480},{"date":"2021-08-06","current":-4.528881,"twenty":-10.248237,"median":6.846307,"eighty":28.260073,"marketCap":432372274},{"date":"2021-08-13","current":-4.254403,"twenty":-10.248237,"median":6.764198,"eighty":27.932296,"marketCap":406167894},{"date":"2021-08-20","current":-4.079306,"twenty":-10.248237,"median":6.643261,"eighty":27.869591,"marketCap":389451306},{"date":"2021-08-27","current":-4.462628,"twenty":-10.248237,"median":6.558893,"eighty":27.869591,"marketCap":426047079},{"date":"2021-09-03","current":-4.429501,"twenty":-10.248237,"median":6.518114,"eighty":27.25394,"marketCap":422884481},{"date":"2021-09-10","current":-4.202347,"twenty":-10.248237,"median":6.504208,"eighty":27.188385,"marketCap":401198098},{"date":"2021-09-17","current":-4.453163,"twenty":-10.248237,"median":6.490303,"eighty":27.188385,"marketCap":425143480},{"date":"2021-09-24","current":-4.609331,"twenty":-10.248237,"median":6.456696,"eighty":26.786502,"marketCap":440052868},{"date":"2021-10-01","current":-4.552543,"twenty":-10.248237,"median":6.448587,"eighty":26.786502,"marketCap":434631272},{"date":"2021-10-08","current":-4.178685,"twenty":-10.248237,"median":6.431205,"eighty":26.786502,"marketCap":398939099},{"date":"2021-10-15","current":-4.278065,"twenty":-10.248237,"median":6.412897,"eighty":26.786502,"marketCap":408426892},{"date":"2021-10-22","current":-4.102967,"twenty":-10.248237,"median":6.403395,"eighty":26.545094,"marketCap":391710305},{"date":"2021-10-29","current":-6.211794,"twenty":-10.248237,"median":6.398297,"eighty":25.567607,"marketCap":404269771},{"date":"2021-11-05","current":-7.797784,"twenty":-10.248237,"median":6.394647,"eighty":25.567607,"marketCap":507487584},{"date":"2021-11-12","current":-7.763004,"twenty":-10.248237,"median":6.380048,"eighty":25.567607,"marketCap":505224036},{"date":"2021-11-19","current":-7.157823,"twenty":-10.248237,"median":6.369098,"eighty":25.567607,"marketCap":465838291},{"date":"2021-11-26","current":-6.78915,"twenty":-10.248237,"median":6.365448,"eighty":25.567607,"marketCap":441844676},{"date":"2021-12-03","current":-5.884858,"twenty":-10.248237,"median":6.358148,"eighty":25.567607,"marketCap":382992414},{"date":"2021-12-10","current":-6.385696,"twenty":-10.248237,"median":6.350848,"eighty":25.203854,"marketCap":415587513},{"date":"2021-12-17","current":-5.982243,"twenty":-10.248237,"median":6.344297,"eighty":25.15722,"marketCap":389330350},{"date":"2021-12-23","current":-6.636116,"twenty":-10.248237,"median":6.332599,"eighty":25.038301,"marketCap":431885063},{"date":"2021-12-31","current":-6.37874,"twenty":-10.248237,"median":6.319963,"eighty":25.019647,"marketCap":415134804},{"date":"2022-01-07","current":-6.810018,"twenty":-10.230852,"median":6.297366,"eighty":24.935704,"marketCap":443202806},{"date":"2022-01-14","current":-6.622204,"twenty":-10.230852,"median":6.24696,"eighty":24.935704,"marketCap":430979643},{"date":"2022-01-21","current":-6.281355,"twenty":-10.230852,"median":-2.065521,"eighty":24.935704,"marketCap":408796868},{"date":"2022-01-28","current":-5.912682,"twenty":-10.230852,"median":-2.405267,"eighty":24.935704,"marketCap":384803253},{"date":"2022-02-04","current":-6.434389,"twenty":-10.230852,"median":-2.492414,"eighty":24.935704,"marketCap":418756481},{"date":"2022-02-11","current":-6.538731,"twenty":-10.230852,"median":-2.528707,"eighty":24.812121,"marketCap":425547127},{"date":"2022-02-18","current":-11.531694,"twenty":-10.382968,"median":-2.576085,"eighty":24.627187,"marketCap":447787215},{"date":"2022-02-25","current":-11.21541,"twenty":-10.57104,"median":-2.598905,"eighty":23.200882,"marketCap":435505583},{"date":"2022-03-04","current":-10.393026,"twenty":-10.715969,"median":-2.619983,"eighty":22.987927,"marketCap":403571593},{"date":"2022-03-11","current":-10.631398,"twenty":-10.774576,"median":-2.634351,"eighty":22.987927,"marketCap":412827822},{"date":"2022-03-18","current":-10.905526,"twenty":-10.912677,"median":-2.664777,"eighty":22.987927,"marketCap":423472485},{"date":"2022-03-25","current":-10.810177,"twenty":-10.912677,"median":-2.687544,"eighty":22.987927,"marketCap":419769994},{"date":"2022-04-01","current":-11.000875,"twenty":-10.954875,"median":-2.702756,"eighty":22.987927,"marketCap":427174977},{"date":"2022-04-08","current":-9.904363,"twenty":-10.965119,"median":-2.723092,"eighty":22.987927,"marketCap":384596323},{"date":"2022-04-14","current":-11.310759,"twenty":-10.977038,"median":-2.732908,"eighty":22.987927,"marketCap":439208075},{"date":"2022-04-22","current":-11.346515,"twenty":-11.045867,"median":-2.739995,"eighty":22.987927,"marketCap":440596509},{"date":"2022-04-29","current":-6.898369,"twenty":-11.08833,"median":-2.772957,"eighty":22.987927,"marketCap":452629607},{"date":"2022-05-06","current":-7.293368,"twenty":-11.08833,"median":-2.787324,"eighty":22.987927,"marketCap":478547049},{"date":"2022-05-13","current":-7.243993,"twenty":-11.08833,"median":-2.809353,"eighty":22.987927,"marketCap":475307369},{"date":"2022-05-20","current":-7.032387,"twenty":-11.08833,"median":-2.821153,"eighty":22.987927,"marketCap":461423025},{"date":"2022-05-27","current":-7.815331,"twenty":-11.08833,"median":-2.839336,"eighty":22.987927,"marketCap":512795097},{"date":"2022-06-03","current":-8.01283,"twenty":-11.08833,"median":-2.846764,"eighty":22.987927,"marketCap":525753818},{"date":"2022-06-10","current":-8.25265,"twenty":-11.08833,"median":-2.86329,"eighty":22.950195,"marketCap":541489408},{"date":"2022-06-17","current":-6.510424,"twenty":-11.08833,"median":-2.873779,"eighty":22.808703,"marketCap":427174977},{"date":"2022-06-24","current":-7.095869,"twenty":-11.092355,"median":-2.884935,"eighty":22.740314,"marketCap":465588328},{"date":"2022-07-01","current":-6.841941,"twenty":-11.092355,"median":-2.900631,"eighty":22.242729,"marketCap":448927116},{"date":"2022-07-08","current":-6.778459,"twenty":-11.092355,"median":-2.914041,"eighty":22.221506,"marketCap":444761813},{"date":"2022-07-15","current":-6.707924,"twenty":-11.092355,"median":-2.935877,"eighty":22.221506,"marketCap":440133698},{"date":"2022-07-22","current":-6.827834,"twenty":-11.092355,"median":-2.964749,"eighty":21.598031,"marketCap":448001493},{"date":"2022-07-29","current":-7.109976,"twenty":-11.092355,"median":-2.981457,"eighty":14.428379,"marketCap":466513951},{"date":"2022-08-05","current":-13.908606,"twenty":-11.214014,"median":-3.008697,"eighty":14.428379,"marketCap":485771960},{"date":"2022-08-12","current":-14.750865,"twenty":-11.31515,"median":-3.093331,"eighty":14.428379,"marketCap":515188698},{"date":"2022-08-19","current":-14.924561,"twenty":-11.452786,"median":-3.123558,"eighty":14.428379,"marketCap":521255232},{"date":"2022-08-26","current":-14.243136,"twenty":-11.514951,"median":-3.169396,"eighty":14.428379,"marketCap":497455754},{"date":"2022-09-02","current":-12.679865,"twenty":-11.786776,"median":-3.199822,"eighty":14.428379,"marketCap":442856952},{"date":"2022-09-09","current":-13.909103,"twenty":-11.969315,"median":-3.240391,"eighty":14.428379,"marketCap":485789343},{"date":"2022-09-16","current":-13.013897,"twenty":-12.264853,"median":-3.260675,"eighty":14.428379,"marketCap":454523362},{"date":"2022-09-23","current":-10.742477,"twenty":-12.364815,"median":-3.316456,"eighty":14.428379,"marketCap":375191769},{"date":"2022-09-30","current":-10.66231,"twenty":-12.364815,"median":-3.346882,"eighty":14.428379,"marketCap":372391831},{"date":"2022-10-07","current":-10.528697,"twenty":-12.364815,"median":-3.402664,"eighty":14.428379,"marketCap":367725266},{"date":"2022-10-14","current":-10.368361,"twenty":-12.364815,"median":-3.437255,"eighty":14.428379,"marketCap":362125389},{"date":"2022-10-21","current":-10.996342,"twenty":-12.364815,"median":-3.453374,"eighty":14.428379,"marketCap":384058241},{"date":"2022-10-28","current":4.198502,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":419846026},{"date":"2022-11-04","current":4.132137,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":413209614},{"date":"2022-11-11","current":4.663812,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":466376540},{"date":"2022-11-18","current":4.500579,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":450053361},{"date":"2022-11-25","current":4.402639,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":440259453},{"date":"2022-12-02","current":4.41663,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":441658583},{"date":"2022-12-09","current":4.439949,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":443990466},{"date":"2022-12-16","current":4.430621,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":443057713},{"date":"2022-12-23","current":4.183439,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":418339756},{"date":"2022-12-30","current":3.973568,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":397352812},{"date":"2023-01-06","current":3.782352,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":378231373},{"date":"2023-01-13","current":4.020206,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":402016577},{"date":"2023-01-20","current":4.141465,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":414142367},{"date":"2023-01-27","current":4.304699,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":430465546},{"date":"2023-02-03","current":4.351337,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":435129311},{"date":"2023-02-10","current":4.225414,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":422537145},{"date":"2023-02-17","current":2.717461,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":398711284},{"date":"2023-02-24","current":2.697672,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":395807841},{"date":"2023-03-03","current":2.69131,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":394874332},{"date":"2023-03-10","current":2.30002,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":337463525},{"date":"2023-03-17","current":1.924636,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":282386490},{"date":"2023-03-24","current":1.918274,"twenty":-12.364815,"median":-3.462583,"eighty":14.428379,"marketCap":281452981},{"date":"2023-03-31","current":2.137778,"twenty":-12.364815,"median":-3.460643,"eighty":14.420662,"marketCap":313659044},{"date":"2023-04-06","current":2.032798,"twenty":-12.364815,"median":-3.464261,"eighty":14.436097,"marketCap":298256144},{"date":"2023-04-14","current":2.035858,"twenty":-12.387741,"median":-3.469294,"eighty":24.238485,"marketCap":298705190},{"date":"2023-04-18","current":2.093117,"twenty":-12.387741,"median":-3.469294,"eighty":24.238485,"marketCap":307106273},{"date":"2023-04-28","current":1.935294,"twenty":-12.479445,"median":-3.489425,"eighty":63.386295,"marketCap":298070069},{"date":"2023-05-05","current":1.922848,"twenty":-12.485747,"median":-3.502846,"eighty":63.559095,"marketCap":296153219},{"date":"2023-05-12","current":1.86062,"twenty":-12.485747,"median":-3.502846,"eighty":63.559095,"marketCap":286568973},{"date":"2023-05-19","current":1.901068,"twenty":-12.485747,"median":-3.502846,"eighty":63.559095,"marketCap":292798733},{"date":"2023-05-26","current":1.798392,"twenty":-12.488898,"median":-3.504523,"eighty":63.645496,"marketCap":276984726},{"date":"2023-06-02","current":1.820172,"twenty":-12.488898,"median":-3.504523,"eighty":63.645496,"marketCap":280339213},{"date":"2023-06-09","current":1.985076,"twenty":-12.488898,"median":-3.504523,"eighty":63.645496,"marketCap":305737466},{"date":"2023-06-16","current":1.863731,"twenty":-12.488898,"median":-3.504523,"eighty":63.645496,"marketCap":287048185},{"date":"2023-06-23","current":1.807726,"twenty":-12.492049,"median":-3.506201,"eighty":63.731896,"marketCap":278422363},{"date":"2023-06-30","current":1.913514,"twenty":-12.4952,"median":-3.52801,"eighty":63.818296,"marketCap":294715582},{"date":"2023-07-07","current":1.897957,"twenty":-12.4952,"median":-3.52801,"eighty":63.818296,"marketCap":292319521},{"date":"2023-07-14","current":1.963296,"twenty":-12.4952,"median":-3.549819,"eighty":63.84186,"marketCap":302382980},{"date":"2023-07-21","current":1.929071,"twenty":-12.4952,"median":-3.556529,"eighty":63.865423,"marketCap":297111644},{"date":"2023-07-28","current":1.888623,"twenty":-12.312661,"median":-3.47936,"eighty":63.865423,"marketCap":290881884},{"date":"2023-08-04","current":1.943758,"twenty":-12.038655,"median":-3.456039,"eighty":63.865423,"marketCap":298001381},{"date":"2023-08-11","current":2.003421,"twenty":-11.817199,"median":-3.441531,"eighty":63.865423,"marketCap":307148435},{"date":"2023-08-18","current":2.031682,"twenty":-11.523066,"median":-3.412492,"eighty":63.865423,"marketCap":311481250},{"date":"2023-08-25","current":1.972019,"twenty":-11.46181,"median":-3.353579,"eighty":63.865423,"marketCap":302334196},{"date":"2023-09-01","current":3.083635,"twenty":-11.344687,"median":-3.31787,"eighty":63.865423,"marketCap":472758250},{"date":"2023-09-08","current":3.089915,"twenty":-11.269161,"median":-3.265746,"eighty":63.865423,"marketCap":473721097},{"date":"2023-09-15","current":3.089915,"twenty":-11.207328,"median":-3.240391,"eighty":63.865423,"marketCap":473721097},{"date":"2023-09-22","current":3.105616,"twenty":-11.074036,"median":-3.208737,"eighty":63.865423,"marketCap":476128217},{"date":"2023-09-29","current":3.096196,"twenty":-11.009751,"median":-3.171892,"eighty":63.865423,"marketCap":474683945},{"date":"2023-10-06","current":3.099336,"twenty":-10.977038,"median":-3.127016,"eighty":63.888987,"marketCap":475165369},{"date":"2023-10-12","current":3.102476,"twenty":-10.950867,"median":-3.110153,"eighty":63.888987,"marketCap":475646793},{"date":"2023-10-20","current":3.102476,"twenty":-10.87609,"median":-3.035741,"eighty":63.936114,"marketCap":475646793},{"date":"2023-10-27","current":3.111896,"twenty":-10.799131,"median":-3.001138,"eighty":63.983242,"marketCap":477091065},{"date":"2023-11-03","current":3.118177,"twenty":-10.747341,"median":-2.978523,"eighty":63.983242,"marketCap":478053912},{"date":"2023-11-10","current":14.367424,"twenty":-10.699594,"median":-2.954645,"eighty":63.983242,"marketCap":479469688},{"date":"2023-11-17","current":14.352941,"twenty":-10.641928,"median":-2.92671,"eighty":63.983242,"marketCap":478986352},{"date":"2023-11-24","current":14.473657,"twenty":-10.602738,"median":-2.914041,"eighty":63.983242,"marketCap":483014881},{"date":"2023-11-28","current":12.062768,"twenty":-10.554667,"median":-2.903703,"eighty":63.998951,"marketCap":402558698}],"updateTime":1746568635326}}}